Lupin Launches Raltegravir Tablets, USP, 600 mg in the United States

Barchart · 1d ago

As the First-To-File, Lupin is Eligible for 180-Day Generic Exclusivity

MUMBAI, India and NAPLES, Fla., Nov. 3, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of Raltegravir Tablets USP, 600 mg in the United States following the approval from the U.S. FDA for its Abbreviated New Drug Application.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.